BioRestorative amends 8-K to clarify auditor change, audit committee probe scope

PUBT · 1d ago
BioRestorative amends 8-K to clarify auditor change, audit committee probe scope
  • BioRestorative filed an amended 8-K to clarify disclosures on its auditor change and related reportable-event discussions with former auditor CBIZ.
  • CBIZ flagged a potential reportable event tied to the suspension of ExoCR and BioX product lines, citing possible implications for prior financial statements.
  • The company said CBIZ had not concluded its prior audit reports or financial statements were unreliable, nor advised investors to stop relying on them.
  • Bush & Associates CPA was engaged to audit fiscal 2026 financials and re-audit fiscal 2025 and 2024.
  • An audit committee investigation into the product suspension remained ongoing, with no new material findings reported to date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098820), on September 10, 2026, and is solely responsible for the information contained therein.